Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0007 0.00 (0.00%)
As of 05/11/2026 01:00 PM Eastern
Compare

SMFL vs. TRVN, NAVB, GNCA, PXMD, and GNCAQ

Should you be buying Smart for Life stock or one of its competitors? The main competitors of Smart for Life include Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry.

How does Smart for Life compare to Trevena?

Smart for Life (NASDAQ:SMFL) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Smart for Life has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Trevena$443K0.02-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Trevena N/A N/A -119.55%

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Trevena Neutral

Smart for Life has a beta of 13.95, indicating that its stock price is 1,295% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Smart for Life beats Trevena on 8 of the 9 factors compared between the two stocks.

How does Smart for Life compare to Navidea Biopharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Navidea Biopharmaceuticals Neutral

Smart for Life has a beta of 13.95, indicating that its stock price is 1,295% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Summary

Smart for Life beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Genocea Biosciences?

Smart for Life (NASDAQ:SMFL) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Smart for Life has a beta of 13.95, meaning that its share price is 1,295% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Genocea Biosciences Neutral

Smart for Life has higher revenue and earnings than Genocea Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

Smart for Life beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Smart for Life compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Smart for Life has a beta of 13.95, indicating that its stock price is 1,295% more volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Smart for Life's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Smart for Life N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Smart for Life Neutral

PaxMedica has higher earnings, but lower revenue than Smart for Life. PaxMedica is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Smart for Life compare to Genocea Biosciences?

Smart for Life (NASDAQ:SMFL) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Smart for Life has a beta of 13.95, suggesting that its stock price is 1,295% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market.

Genocea Biosciences has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

28.4% of Smart for Life shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Genocea Biosciences N/A N/A N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Genocea Biosciences Neutral

Summary

Smart for Life beats Genocea Biosciences on 5 of the 5 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifeMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$5K$3.74B$6.24B$12.14B
Dividend YieldN/AN/A2.78%5.23%
P/E Ratio0.009.2020.6725.38
Price / Sales0.002.03547.4175.53
Price / CashN/A7.5327.8136.29
Price / Book0.001.599.596.65
Net Income-$22.68M$10.91M$3.54B$333.19M
7 Day PerformanceN/A2.81%-0.45%-0.55%
1 Month PerformanceN/A4.96%5.68%7.66%
1 Year PerformanceN/A11.56%38.47%35.65%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat		N/A-53.3%$5K$11.11MN/A110
TRVN
Trevena
N/A$0.01
flat		N/A-99.1%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 5/12/2026 by MarketBeat.com Staff.
From Our Partners
Trump is positioned. Elon lights the fuse.
On Thursday, the Senate Banking Committee votes on the CLARITY Act. A bill that would create the first real le...
Crypto 101 Media | Sponsoredtc pixel
Iran broke the petrodollar…
For 50 years, every barrel of oil settled in dollars - that rule is what made the dollar the world's reserve c...
Golden Portfolio | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
BSEM: From OTC to Nasdaq Contender!
BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...
Huge Alerts | Sponsoredtc pixel
If You Have $50k+ on Coinbase, This Will Ruin Your Day
In 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...
Decentralized Masters | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Nevada gold explorer near Kinross district draws attention
Gold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...
Wall Street Logic | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel